Close Menu

NEW YORK – Interpace Biosciences has experienced a busy year in both diagnostic development and biopharma services, including securing insurance coverage for multiple tests, a business acquisition, and a company rebranding to reflect the resulting expansion.

The Parsippany, New Jersey-based firm now aims to expand current relationships with multiple biopharmaceutical companies as it bolsters its service offerings for cancer therapeutics firms and, eventually, drug developers in other disease indications. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.